NYU Langone launches program to target pancreatic cancer

The Perlmutter Cancer Center at NYU Langone Medical Center has launched their new Pancreatic Cancer Center, a multidisciplinary center to improve the diagnosis, treatment and prevention of pancreatic cancer, according to a press release.

The Pancreatic Cancer Center intends to create an environment where science and industry can collaborate on the development of new technologies and therapies, enabling researchers to create a comprehensive care model that will fight pancreatic cancer.

“Advances in many areas of cancer biology and genomics have created an unprecedented opportunity to drive discoveries that have real impact on patients, especially those with lethal diseases like pancreatic cancer,” Diane M. Simeone, MD, associate director of translational research at the Perlmutter Cancer Center, incoming chair of Scientific and Medical Advisory Board of the Pancreatic Cancer Action Network and director of the Pancreatic Cancer Center, said in the release. “It is our obligation to step up to this challenge.”

The Pancreatic Cancer Center will work on identifying biomarkers for early detection, focusing on research that will help manage pancreatic tumors and allow clinical practices to receive laboratory test results faster. It will also evaluate genetic predisposition and risk factors for pancreatic cancer. Because of their emphasis on care and advancing research, the Pancreatic Cancer Center will enable patients to communicate with top clinicians and have the opportunity to enroll in clinical trials on new drugs that fight pancreatic cancer.

“In the past, pancreatic cancer took a back seat to the investigation of other forms of cancer, but the increasing number of cases has changed that,” Simeone said. “We will advance the most promising laboratory findings to the clinic in the shortest possible time, improve clinical trial design and efficiency, facilitate data sharing and capitalize fully on technologic advances that will one day lead us to an early detection test for pancreatic cancer.”

Disclosure: Simeone is associate director of translational research at the Perlmutter Cancer Center, incoming chair of Scientific and Medical Advisory Board of the Pancreatic Cancer Action Network and director of the Pancreatic Cancer Center.

The Perlmutter Cancer Center at NYU Langone Medical Center has launched their new Pancreatic Cancer Center, a multidisciplinary center to improve the diagnosis, treatment and prevention of pancreatic cancer, according to a press release.

The Pancreatic Cancer Center intends to create an environment where science and industry can collaborate on the development of new technologies and therapies, enabling researchers to create a comprehensive care model that will fight pancreatic cancer.

“Advances in many areas of cancer biology and genomics have created an unprecedented opportunity to drive discoveries that have real impact on patients, especially those with lethal diseases like pancreatic cancer,” Diane M. Simeone, MD, associate director of translational research at the Perlmutter Cancer Center, incoming chair of Scientific and Medical Advisory Board of the Pancreatic Cancer Action Network and director of the Pancreatic Cancer Center, said in the release. “It is our obligation to step up to this challenge.”

The Pancreatic Cancer Center will work on identifying biomarkers for early detection, focusing on research that will help manage pancreatic tumors and allow clinical practices to receive laboratory test results faster. It will also evaluate genetic predisposition and risk factors for pancreatic cancer. Because of their emphasis on care and advancing research, the Pancreatic Cancer Center will enable patients to communicate with top clinicians and have the opportunity to enroll in clinical trials on new drugs that fight pancreatic cancer.

“In the past, pancreatic cancer took a back seat to the investigation of other forms of cancer, but the increasing number of cases has changed that,” Simeone said. “We will advance the most promising laboratory findings to the clinic in the shortest possible time, improve clinical trial design and efficiency, facilitate data sharing and capitalize fully on technologic advances that will one day lead us to an early detection test for pancreatic cancer.”

Disclosure: Simeone is associate director of translational research at the Perlmutter Cancer Center, incoming chair of Scientific and Medical Advisory Board of the Pancreatic Cancer Action Network and director of the Pancreatic Cancer Center.